Windward Bio raises $165M crossover round with RTW Investments participation

  • Windward Bio, private clinical-stage biotech developing long-acting immunology antibodies for respiratory and dermatology diseases, raised an upsized USD 165 million crossover financing.
  • Round was led by OrbiMed, with participation from existing investors including RTW Investments LP.
  • Proceeds extend cash runway, funding multiple clinical readouts over next 12 months.
  • Capital supports Phase 2/3 POLARIS asthma program for lead anti-TSLP antibody WIN378, with initial Phase 2 data expected in 2H 2026.
  • Funding also backs WIN027, a long-acting bispecific antibody targeting TSLP and IL-13, with Phase 1 data expected by end of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RTW Investments LP published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.